We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Werewolf Therapeutics Inc | NASDAQ:HOWL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.52 | -9.34% | 5.05 | 4.58 | 12.77 | 5.61 | 5.02 | 5.61 | 91,420 | 01:00:00 |
A live webcast link for the Leerink Partners Global Biopharma Conference fireside chat will be available at https://investors.werewolftx.com/news-and-events/events. An archived replay will be available for approximately 90 days following the event.
About Werewolf Therapeutics:
Werewolf Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) in multiple solid tumor types. WTX-330 is in development as a single agent in refractory and/or immunotherapy unresponsive or resistant advanced or metastatic solid tumors and non-Hodgkin lymphoma. To learn more visit www.werewolftx.com.
Investor Contact:Josh Rappaport Stern IR 212.362.1200Josh.Rappaport@sternir.com
Media Contact:Amanda SellersVERGE Scientific Communications 301.332.5574asellers@vergescientific.com
Company Contact:Ellen LubmanChief Business Officer Werewolf Therapeutics elubman@werewolftx.com
1 Year Werewolf Therapeutics Chart |
1 Month Werewolf Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions